Diagnostic Array Comparative Genomic Hybridization Is It Ready for Prime Time? by Done, Susan B.
Guest Editorial
Diagnostic Array Comparative Genomic
Hybridization
Is It Ready for Prime Time?
In this issue of The Journal of Molecular Diagnostics, we
feature two articles that offer different perspectives on an
emerging field of diagnostic technology. Comparative
genomic hybridization (CGH) allows a simultaneous as-
sessment of copy number across the whole genome. It
involves the competitive hybridization of a reference and
sample of interest to an immobilized target sequence.
Imbalances caused by gene deletion or amplification will
lead to fluorescently detectable signals on the array. This
information in turn can be used to map regions of abnor-
mality at a level of distinction that surpasses conventional
karyotyping. Although metaphase chromosomes were
the initial targets used in array CGH,1 recent advances in
array technologies use oligonucleotides, single-nucleo-
tide polymorphisms, cDNAs, and bacterial artificial chro-
mosomes, and offer the potential for higher resolution
analysis.
Thus far, array CGH has been used extensively in
research but is a relative newcomer to the diagnostic
arena. In the two articles that follow, Bejjani and Shaffer2
and Veltman and de Vries3 present two very different
visions of how this technology may be used in the diag-
nostic setting. Bejjani and Shaffer have chosen to take a
targeted approach, whereas Veltman and de Vries prefer
whole-genome coverage. It remains to be seen which of
these approaches will become more widely adopted in
the clinical laboratory. A number of factors are likely to
influence the choice of individual centers, including the
cost relative to the incremental value gained by a broader
coverage. Complicating factors such as copy number
polymorphisms in normal individuals have only been de-
scribed recently.4,5 Progress in our understanding of how
wide the degree of variation is between individuals may
also play a role in the evolution of array CGH.
Development of expression array analysis has pre-
ceded array CGH in terms of clinical uptake. Here, similar
discussions occur regarding the utility and practicality of
whole-genome expression characterization or the use of
smaller panels of significantly altered genes. Further-
more, expression of genes identified by array analysis as
having prognostic or predictive value may be incorpo-
rated into even more targeted polymerase chain-reaction
or immunohistochemical tests.6
We are at an exciting stage in the development of
diagnostic array CGH. Increasing large-scale studies us-
ing this technology may ultimately demonstrate whether
one approach, broad versus targeted analysis, is supe-
rior for the clinical laboratory. The discussion will continue
as clinical laboratories evaluate the utility and potential of
this application. However, at the outset one thing seems
clear: diagnostic array CGH is likely to have broad and
far-reaching implications for the diagnostic community.
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